MassBio Board of Directors

Glenn Batchelder

Glenn Batchelder was most recently co-founder and CEO of Civitas Therapeutics, a pulmonary delivery company with a lead program for treating Parkinson’s disease that was acquired by Acorda Therapeutics.   Prior to Civitas, he was the founding CEO of BIND Therapeutics (BIND), a leading nanotherapeutics company.  Prior to BIND, Mr. Batchelder was the initial CEO of Acceleron Pharma (XLRN) an oncology and supportive care biotherapeutics company.   Prior to Acceleron, Mr. Batchelder was Senior Vice President of Operations at Millennium Pharmaceuticals where he played an integral leadership role in the launch of VELCADE® and was responsible for the commercial supply chain and technical operations for INTEGRILIN®.   Mr. Batchelder received a BS in Chemical Engineering from Lehigh University.

Dr. Abbie Celniker, Ph.D.
Vice Chairman

Abbie Celniker, Ph.D is the CEO of Eleven Bioptherapeutics, a publically traded biopharmaceutical company focused on engineering and developing innovative protein-based therapies to treat ocular diseases.  Dr. Celniker has been in the biotechnology and pharmaceutical industry for over 25 years where she has worked in small and mid-sized biotechnology companies as well as mid-sized and large pharmaceutical companies  Prior to Eleven, Abbie was head of Translational Medicine at Alexion Pharmacueticals by way of  the acquisition of Taligen Therapeutics where she was the President and CEO.  Prior to joining Taligen, Dr. Celniker was  the Global Head of Novartis Biologics where she was responsible the oversight of the discovery and development of the Novartis biologics pipeline.  Dr. Celniker has also been the Global Head of the  Program Office for the Novartis Institutes for Biomedical Research (NIBR)  where she was responsible for the global integration and oversight of the Novartis Discovery Portfolio.  In a previous role at Millennium Pharmaceuticals, Dr. Celniker led the pipeline portfolio review committee and headed Development Project Management and Pharmaceutical Sciences.    Prior to Millennium, Dr. Celniker was at Wyeth, where she was assistant vice president for predevelopment and biopharmaceutical core technologies. She has previously held positions at Genetics Institute, Genentech Inc. and the University of Arizona Cancer Center. Dr. Celniker is a member of the MassBio board of directors, is the chair of the board of directors of ImaginAb, and a member of the scientific advisory board for Adimab.  Dr. Celniker has a bachelor's degree in biology from the University of California at San Diego and earned her Ph.D. in molecular biology at the University of Arizona.

Michael O'Hara

Mr. O'Hara is a partner and leads the life sciences audit practice of Deloitte in Boston.  In addition to serving many life sciences companies in various capacities, Mr. O'Hara also serves as audit partner for publicly traded and private life sciences companies and a large integrated healthcare system, and therefore has a comprehensive understanding of the healthcare industry.  Mr. O'Hara has been involved in several IPOs, mergers and acquisitions engagements, financial forecasting projects, and value-added projects on accounting and financial reporting.  Mr. O'Hara has assisted his clients through product launches and rapid growth phases including advising on financial and operational infrastructure challenges.  In addition to his role as Treasurer of the Massachusetts Biotechnology Council, Mr. O'Hara is a member of the Board of Directors of the Massachusetts Medical Device Industry Council (MassMEDIC) and the Medfield Youth Hockey Association.  He is also a member of the AICPA and the Massachusetts Society of CPAs and is an adjunct professor of accounting and auditing at Boston College.

Mr. O'Hara received his BA from Oneonta State University and his MBA from Boston College.  He lives in Medfield, MA with his wife Maryclare, son Liam and daughter Maeve.

David Lucchino

David Lucchino is the CEO of Entrega, a biotechnology company co-founded by MIT Institute Professor Robert S. Langer, Sc.D and PureTech Ventures. David also holds an Entrepreneur in Residence position at PureTech Ventures.

Previously David was the Chief Executive Officer and President of Semprus BioSciences until its acquisition by Teleflex Medical, Inc. (NYSE: TFX). He then served as a Vice President executing the post-M&A integration plan for eighteen months. David co-founded Semprus BioSciences while attending the Massachusetts Institute of Technology with Robert S. Langer, Sc.D.

Under his stewardship, Semprus BioSciences grew from two to 50 employees, secured $28.5 million in venture capital financing as well as $8.4 million in federal funding and received approval from the FDA and European regulators for its first medical device product within five years of the company founding.

Prior to co-founding Semprus, David was a Senior Associate at Polaris Venture Partners, a multibillion dollar venture capital fund based in Boston. Previously, David co-founded and served as Managing Director of LaunchCyte, an investment firm that specializes in acquiring and developing biomedical intellectual property.

David began his career as a technology marketing executive. He earned his MBA as an Alfred P. Sloan Fellow at the Massachusetts Institute of Technology. He also earned a Master of Science degree from Syracuse University and a Bachelor of Arts degree from Denison University.

David is a member of the Board of Directors of the Massachusetts Biotechnology Council (Mass Bio), where he serves on the executive committee. He is a Trustee of Mt. Auburn Hospital, a Harvard Medical School facility, where is Chairman of the Audit Committee, Babson College and the Multiple Myeloma Research Foundation.

Outside the office, David is active with the National Outdoor Leadership School (NOLS), where he was part of an expedition that climbed Alaska’s Mt. McKinley, North America's tallest mountain, and spent 95 days living in the Rocky Mountains as part of a leadership training program. He most recently rafted down Idaho’s “River of No Return,” the Salmon River, with NOLS. David has participated as part of the Boston Red Sox “Team 9” in the Pan-Mass Challenge, the annual two-day bike ride that raises funds for adult and pediatric cancer care and research at Dana-Farber Cancer Institute.

Geoff MacKay
Immediate Past Chairman

Geoff MacKay has served as President and Chief Executive Officer at Organogenesis Inc., a leading regenerative medicine company, since December 2003. In his role, Mr. MacKay provides the company with significant global and commercial experience spanning both the pharmaceutical and
biotechnology sectors.

Prior to joining Organogenesis, Mr. MacKay held numerous leadership positions within Novartis AG, such as Vice-President and Business Unit Head, Transplantation and Immunology at Novartis Canada, Vice-President of Tissue-Engineering in Novartis USA, Head of Global Sales Immunology and Transplantation based in Basel, Switzerland, and Sales and Marketing Manager of Novartis Biotech Europe.

Mr. MacKay has been specifically involved in the emerging field of regenerative medicine for the last 15 years, most notably taking Apligraf® from development to full-scale commercialization.

Mr. MacKay currently serves as Chairman of the Board of the Alliance for Regenerative Medicine (ARM), a Washington DC-based multi-stakeholder advocacy group whose mission is to advance the field of regenerative medicine. ARM’s 150 members include companies, academic research institutions, patient advocacy groups, foundations, health insurers and investors dedicated to improving patients’ lives through regenerative medicine therapies. Most recently he served for two years as the Chairman of the Board of Directors for the Massachusetts Biotechnology Council (MassBio), the oldest biotechnology trade association in the U.S., comprising 600 companies, universities, academic institutions and other organizations dedicated to advancing cutting edge research.

Additionally, he is an Advisory Council member for the Health Policy Commission (HPC) for the Commonwealth of Massachusetts, a state agency that monitors the reform of the healthcare delivery and payment systems in Massachusetts, and develops health policy to reduce overall cost growth while improving the quality of patient care.

Through his work with Organogenesis, MassBio, ARM and the HPC, Mr. MacKay is dedicated to applying innovation to reshape and improve the current quality of healthcare.

Caren Arnstein

Caren Arnstein is Senior Vice President and Head of Communications for Genzyme, a Sanofi company, one of world’s leading biotechnology companies.  As part of the executive leadership team, Caren oversees Genzyme’s global Corporate Communications, State and local Public Affairs and Community Relations functions.  Under her leadership, Genzyme has built a positive reputation as an innovative and socially responsible company – committed to improving the lives of people with debilitating diseases.  

Caren provides strategic direction for external and internal communications programs, including media relations, leadership communications and issues management.  In her 16 years with Genzyme, she has lead major initiatives for product launches, mergers and acquisitions, shareholder activism, and product supply challenges.  Caren works closely with government relations colleagues to help communicate Genzyme’s position on the many public policy issues affecting the life sciences industry.    

In addition, Caren oversees global corporate citizenship programs, supporting employee-initiated volunteer activities in our communities.  She leads the company’s charitable grants advisory board and community relations programs focused on addressing science education and health needs.  She also serves on the State Board for the March of Dimes and the Greater Boston Chamber of Commerce Board of Directors.  

Caren has more than 25 years of communications experience in the life sciences.  Prior to joining Genzyme in 1995, she worked in the environmental services field as a consultant to leading companies and communities on a broad range of environmental communication projects.  Caren earned an M.S. in Communication Management from Simmons College and a B.S. in Environmental Science from the University of Massachusetts at Amherst.   

Mark R. Bamforth

Mark Bamforth is the founder, President and CEO of Gallus BioPharmaceuticals, a premier contract manufacturer delivering clinical and commercial biopharmaceuticals to pharma and biotech companies worldwide. Since the acquisition of a world-class facility in 2011, making two lead commercial products for Janssen, Gallus has more than doubled through organic growth and a merger with another CMO, Laureate Biopharma, in 2013.

Bamforth has 22 years of previous experience in the UK and USA running global operations and a pharmaceutical CMO business for Genzyme, a leading biotechnology company. He began his career as a chemical engineer in the whisky industry and as a petroleum engineer exploring for North Sea oil.

Bamforth serves on the MassBio Board and is a Saltire Foundation Founding Trustee, enabling young Scottish entrepreneurs to expand their business knowledge through education and internships with high growth USA companies. He has a BS in Chemical Engineering and an MBA.

Margaret Chu-Moyer, Ph.D.

Margaret Chu-Moyer is Executive Director, Research and Amgen Massachusetts Site Head.  In addition to Margaret’s role as Site Head for Amgen’s Cambridge, Massachusetts research facility, she is responsible for medicinal chemistry efforts in Cambridge and South San Francisco, as well as chemistry outsourcing.  She has been at Amgen since 2009.  Prior to joining Amgen, Margaret led both medicinal chemistry and hit-to-lead groups at Pfizer Global Research and Development in Groton, CT in the Cardiovascular, Metabolic and Endocrine Diseases therapeutic area.

Margaret received a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in Organic Chemistry from Yale University, where her research focused on natural products total synthesis.  Margaret currently serves on the Boston Children’s Hospital, Technology & Innovation Development Office, Technology Development Fund Advisory Board, the Massachusetts Biotechnology Council Board of Directors, the Health Leads Boston Council and the American Chemical Society Medicinal Chemistry Long Range Planning Committee.  She was recently recognized as one of Mass High Tech’s 2011 Women to Watch.

Timothy P. Clackson, Ph.D.

Tim Clackson is President of Research and Development and Chief Scientific Officer at ARIAD Pharmaceuticals Inc., an integrated global oncology company headquartered in Cambridge, Massachusetts and Lausanne, Switzerland.

During his 20 year career at ARIAD, Dr. Clackson has held a series of increasingly senior positions, including President of R&D since 2010 and CSO since 2003. Dr. Clackson has overall operational and strategic responsibility for R&D – about half of ARIAD – including drug discovery, preclinical and translational research, clinical development, and manufacturing and technical operations. He led the multi-disciplinary R&D team that discovered and developed Iclusig® (ponatinib), an oral tyrosine kinase inhibitor now marketed in the U.S., EU and Switzerland; AP26113, a next-generation oral inhibitor of anaplastic lymphoma kinase (ALK) currently in a pivotal phase 2 study in lung cancer patients; and ridaforolimus, an mTOR inhibitor that was licensed to Merck for oncology, and is also being studied clinically as a component of drug-eluting stents.

Dr. Clackson joined ARIAD in 1994 as a scientific group leader in chemical biology, as part of a team developing a novel platform technology for controlling cell therapies with small-molecule drugs. He subsequently assumed leadership of this team and was instrumental in out-licensing the platform to specialty companies following non-clinical proof-of-concept. The technology remains in active development, with clinical proof-of-concept now obtained by licensee Bellicum Pharmaceuticals.  In 2001, Dr. Clackson focused ARIAD research on oncology, centered on platforms of structure-based design and predictive in vitro resistance screens. Subsequently he has led the discovery and development of three oncology product candidates to date, from concept through discovery, development and ongoing approval. Iclusig, ARIAD’s first product, was approved less than five years after first-in-man testing, and provided the first and only therapy for chronic myeloid leukemia (CML) patients with the T315I mutation, as well as potent option for other forms of resistant CML.

Dr. Clackson’s current responsibilities and interests straddle R&D and a broader role in corporate leadership. He has been an invited speaker at scientific and medical conferences including the AACR, ACS and ASBMB annual meetings. He is also a frequent company spokesperson at investor conferences, and has presented and been a panel member at industry forums including the BIO Annual Meeting. He serves as a board observer for ReGenX Biosciences, a licensee of ARIAD’s platform technology. At ARIAD, he is a member of the Executive Leadership Team, chairs the R&D Leadership Team, and is involved directly in broad areas of corporate leadership and strategy. Dr. Clackson was instrumental in leading ARIAD through the challenges resulting from new safety data on Iclusig in the fall of 2013, which led to the temporary suspension of marketing in the U.S.; navigating the regulatory challenges, working through difficult internal decision-making, and overseeing the evolution and rebuilding of the company.

Dr. Clackson’s education and training provided him with an early exposure to biotechnology. Prior to ARIAD, he was a postdoctoral fellow at Genentech Inc. His research on the human growth hormone receptor, with Dr. James A. Wells, led to a highly-cited paper that defined the now-established “hot spot” paradigm for how proteins interact, that was broadly influential in the field of drug discovery.  His graduate research, conducted with Dr. Greg Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK), included the development of antibody phage display library technology. This led directly to the founding of Cambridge Antibody Technology (CAT) and the subsequent development of multiple approved antibody products including Humira (adalimumab).  Dr. Clackson has published approximately 85 scientific papers and is a co-inventor on 15 issued U.S. patents. He received his Ph.D. in Biology from Cambridge University in 1991. He received his B.A. degree in Biochemistry from Oxford University in 1987.

Dr. Clackson was born in the UK, and enjoys dual UK and U.S. citizenship. He is active in the Boston-area biotechnology community, notably in the British expatriate community as a leading member of the Boston Biotech Brits organization. He has been active with MassBio, delivering keynote introductions at the annual meeting in recent years, and facilitating MassBioEd on-site student initiatives at ARIAD. Dr. Clackson and his family reside in Lexington.

Geoffrey F. Cox, Ph.D.

Dr. Cox is a Partner at Red Sky Partners LLC, a firm providing corporate strategy, business development and virtual and transition operating management services to clients in the biotechnology and biopharmaceuticals industry. He has over 35 years of pharmaceutical and biotechnology experience in a broad range of senior management positions in operations management, as a CEO and as a member of the board of public and private companies.

In 1984, Dr. Cox joined Genzyme Corporation in the U.K. and then, in 1988, became Senior Vice President, Operations, in the U.S. Dr. Cox later became Executive Vice President responsible for operations and the pharmaceutical, diagnostic and genetics business units of Genzyme. Prior to joining Genzyme, Dr. Cox was General Manager of the U.K. manufacturing operations for  Gist-Brocades.

In 1997, Dr. Cox became Chairman and CEO of Aronex Pharmaceuticals, Inc., based in The Woodlands, Texas, and subsequently, in July 2001, he became Chairman, President and CEO of GTC Biotherapeutics, Inc., based in Framingham, Massachusetts, a position he held until June 2010.

Dr. Cox is non-executive Chairman of the Board of Nabi Biopharmaceuticals and a Director of Gallus Biopharmaceuticals. He also served for a number of years on the Board of the Biotechnology Industry Organization and also as a member of their Emerging Companies Section and Healthcare Section Governing Body Committees.

Dr. Cox received a B.Sc. (Hons) in Biochemistry from the University of Birmingham, U.K. and a Ph.D. in Biochemistry from the University of East Anglia, U.K.

Jeffrey Elton

Jeff Elton, PhD is Global Managing Director for Accenture Strategy and Global Lead for Accenture’s Predictive Health Intelligence.  Jeff has over 20 years of experience as a global executive and consultant in the biopharmaceutical and healthcare sectors. Jeff serves clients in pharmaceutical, biopharmaceutical, diagnostics, devices and health provider sectors. Jeff is a Board Member and senior advisor to early stage companies in diabetes, oncology therapeutics, oncology diagnostics, and Health IT.

Prior to Accenture, Jeff was founding CEO of the Personalized Oncology Company, KEW Group; Senior Vice President of Strategy and Global Chief Operating Officer at Novartis Institutes of BioMedical Research, Inc. (NIBR); and senior partner with McKinsey & Company in that firm's Pharmaceutical & Medical Products practice. Jeff has an MBA and PhD from the University of Chicago Booth School of Business.  

Chris Garabedian

Chris Garabedian is a biotechnology executive that most recently served as the President and Chief Executive Officer of Sarepta Therapeutics from January 2011-March 2015 and as a member of Sarepta's board of directors from June 2010-March 2015.

Mr. Garabedian served as Vice President of Corporate Strategy for Celgene Corporation, a publicly-traded integrated global biopharmaceutical company, from July 2007 to December 2010, where he was responsible for assessing all potential business development transactions.

From November 2005 to June 2007, Mr. Garabedian served as an independent consultant to early-stage biopharmaceutical companies. From 1997 to 1998 and from 1999 to November 2005, Mr. Garabedian worked at Gilead Sciences, Inc., a publicly-traded biopharmaceutical company, where he served in a number of global leadership roles, including as Vice President of Corporate Development, Vice President of Marketing, and Vice President of Medical Affairs. While at Gilead Sciences, Mr. Garabedian's responsibilities included managing corporate development initiatives, including portfolio review and planning, mergers and acquisitions and in-licensing activities, and leading four global product launches. Mr. Garabedian also held various commercial roles at COR Therapeutics, Inc. from 1998 to 1999 and at Abbott Laboratories from 1994 to 1997.

He started his biopharmaceutical career as a consultant with Migliara/Kaplan Associates from 1991 to 1994.

Mr. Garabedian received his B.S. in marketing from the University of Maryland.

Scott Gillis

Scott H. Gillis is CEO of Onsite Therapeutics, Inc. and also an independent consultant with more than 37 years' experience in the pharmaceutical and medical device industry in capacities ranging from sales and marketing positions to general management. He has extensive experience in the fields of dermatology, anti-infective, cardiovascular, oncology, psychiatric, orthopedic, dental and wound care products. His experience includes the advancement of medical ideas from research and development to commercial products, securing financing, and negotiating sales, marketing and distribution partnerships with major healthcare corporations.

Prior to becoming CEO of OnSite Therapeutics, Inc. and consulting, Mr. Gillis served as President and CEO of NUCRYST Pharmaceuticals, Inc. for 8 years. He took NUCRYST public on the NASDAQ and TSX in 2005. Mr. Gillis also served as President and CEO of Li Medical, a private medical device company, for 5 years. Prior to Li Medical, Mr. Gillis spent 15 years at Bristol-Myers Squibb where he worked in a number of divisions including Squibb, Westwood, Mead Johnson Pharmaceuticals, ConvaTec and Mead Johnson Oncology. At ConvaTec, he served as Vice President and General Manager of ConvaTec USA and later as Global Vice President, Wound and Skin Care.

A Boston native, Mr. Gillis has an MBA from Xavier University and a BA in Biology and Chemistry from Salem State College.

Steven C. Gilman, Ph.D.

Steve Gilman is the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals. Prior to joining Cubist, Dr. Gilman served as Chairman of the board of directors and CEO of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation, responsible for all aspects of the Inflammation business from early gene discovery to product commercialization. Prior to Millennium, he was Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas.  Dr.  Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College.

He currently  serves  on  the  board  of  directors  of  the  Massachusetts  Biotechnology  Association, Inhibikase, Inc., a privately held biotechnology company, and TransCelerate Biopharma, Inc., a nonprofit organization emphasizing increased quality in clinical studies and improved patient safety.  In addition, Dr. Gilman serves on the Biomedical Advisory Council of PhRMA and the Penn State University Biotechnology Advisory Board.

Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.

Sam Guhan

Sam Guhan received his PhD in Chemical Engineering from Rensselaer (Troy, NY). He has 25 years of experience in the field of process development in the biotech/ pharma industry.  Guhan joined Amgen in 2003 and led the Process & Product Development (P&PD) group at Amgen’s Thousand Oaks site until 2011. He then transferred to the Process & Product Engineering (P&PE) group, which supports the late stage pipeline and commercial products at Amgen. He is currently the Vice President responsible for Drug Substance activities within the Process Development organization.  Prior to Amgen, Guhan was at Pfizer’s BioProcess R&D group located at Groton, CT. Guhan is also involved in various external professional/scientific organizations. He served as the Treasurer of the Biotechnology Division of the American Chemical Society, and received the ACS Van Lanen award for his services to this organization. He was part of the Amgen Bioprocessing Center Advisory Board (ABCAB) at the Keck Graduate Institute (KGI). Guhan currently serves on the Governing Council of the LGO (Leaders in Global Ops group) at MIT.

Jose-Carlos Gutierrez-Ramos, Ph.D.

Dr. Gutierrez is Senior Vice President and head of the BioTherapeutics Research Group, which includes three Research Units (RUs), the global Pharmacokinetics, Dynamics and Metabolism - New Biological Entities (PDM-NBE) department, and the Global BioTherapeutic Technologies (GBT) department.

Prior to joining Pfizer, Dr. Gutierrez was SVP and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK. Dr. Gutierrez built the iiCEDD as a global group of "drug hunters"  that included biologists, chemists, pharmacologists, protein scientists and clinicians who were responsible for the discovery of drugs in that space all the way to Phase IIa (POC).

Prior to GSK he served at AMGEN Mountain View as Site Head and CSO. Previous to the AMGEN acquisition of Avidia he was the SVP of R&D, where he led a significant effort of novel protein therapeutics for autoimmune disease. Before his AVIDIA appointment, he served as CSO of Peptimmune Inc. in Cambridge where he was responsible for the development of peptide based therapeutics for autoimmune disease, including MS and diabetes. Before Peptimmune, Dr. Gutierrez served as Vice President, Inflammation at Millennium Pharmaceuticals, where he built and led a group of more than 150 scientists.

Dr. Gutierrez was also a faculty member at the Genetics department of Harvard Medical School, where he led a research team at the Center for Blood Research. Before coming to the US, he was member of the Basel Institute for Immunology in Basel, Switzerland and a fellow at the Max-Plank for Immunbiologie in Freiburg, Germany. Dr. Gutierrez received his masters in Chemistry and his Ph.D. in Immunology from the Autonoma University of Madrid, Spain.

Edwin M. Kania, Jr.

Ed Kania is Managing Partner and Chairman of Flagship Ventures. Ed has 30 years of experience in the  venture capital industry. Prior to co-founding Flagship Ventures in 2000, he spent 14 years as General Partner  of OneLiberty Ventures and of its predecessor firm, Morgan, Holland Ventures. His direct investment  experience covers over 100 companies. In addition, he has been intimately involved in the launch and  development of more than 20 companies as the founding, lead or co-lead investor, and on occasion has  assumed operating roles in support of management. Mr. Kania is currently a director of Acceleron Pharma  (Nasdaq: XLRN), Blend Therapeutics, DataCore Software, EcoSense Lighting, Oasys Water, Selecta Biosciences,  TARIS Biomedical, TransMedics, and Visterra. He is also a member of The Johns Hopkins Medicine Alliance for  Science and Technology Development Industry, and a member of Partners Healthcare Innovation Advisory  Board. Ed earned his undergraduate degree in physics from Dartmouth College and his MBA from Harvard  Business School.

Laurie Bartlett Keating

Laurie Bartlett Keating joined Alnylam in 2014 with more than 25 years of executive experience at high technology and biotechnology companies. Prior to joining Alnylam, Laurie served as Senior Vice President, General Counsel and Secretary of Millennium: The Takeda Oncology Company for 9 years, responsible for setting the company’s global legal, intellectual property, and corporate quality strategies and priorities. Prior to Millennium, Laurie was co-founder and the first CEO of Hydra Biosciences, Inc. Before co-founding Hydra, she served as an executive at high growth technology companies, including serving as Senior Vice President, General Counsel and Secretary of Iomega Corporation, and Sybase, Inc., a software company that grew from a few hundred to 6,000 employees during Laurie’s tenure on the management team. Based on her leadership at Sybase, she was named as one of the 45 most influential in-house lawyers in the United States under the age of 45. Upon graduating from law school, Laurie practiced law at McCutchen, Doyle, Brown and Enersen (now Bingham McCutchen) in San Francisco. She has a Doctor of Jurisprudence from the University of California, Hastings College of the Law, and a Bachelor of Arts in Economics from the University of California at Berkeley. Laurie is a member of the Board of Directors of MassBio and the immediate past chair of the BIO General Counsels Committee.

Melissa Bradford Klug

Melissa Klug joined AMAG in June 2014 as senior vice president of business development and strategy. Prior to joining AMAG, Ms. Klug served as vice president of corporate development at Mallinckrodt Pharmaceuticals since 2004 and during that time, completed a number of significant transactions, including two corporate development transactions within six months of Mallinckrodt’s spin out of Coviden. Prior to joining Mallinckrodt, Ms. Klug held leadership roles in business development at Baxter International and Eli Lilly and Company.

Ms. Klug has more than 15 years of hands-on strategic planning, licensing, and business development experience in the life sciences industry. She has executed multiple business development transactions and established key financial metrics to support investments or acquisitions of new technologies, assets and companies, including the acquisition of CNS Therapeutics and two Phase III assets that formed the foundation for a pain franchise and generated more than $250 million in revenue annually. Ms. Klug holds a Bachelor of Science degree in Chemistry from Maryville University and a Master of Business Administration from DePaul University.

Mark Leuchtenberger

Mark Leuchtenberger joined Acusphere, Inc. as President and Chief Executive Officer in 2013, bringing experience in commercial operations, business development and preparing biopharmaceutical companies for product approval and commercialization. Mr. Leuchtenberger most recently served as President, Chief Executive Officer and a member of the board of directors at Rib-X Pharmaceuticals (now Melinta) until its acquisition. Prior to Rib-X, Mr. Leuchtenberger served as President and Chief Executive Officer of Targanta Therapeutics Corporation, where he led the company’s initial public offering in 2007 and its acquisition in 2009. From 2002 to 2006 Mr. Leuchtenberger served as the President and Chief Executive Officer of Therion Biologics Corporation, a privately held cancer vaccine company. Prior to Therion, Mr. Leuchtenberger was a senior officer at Biogen Idec Inc., where he led the Avonex® development and launch in the United States and subsequently managed North American and international commercial operations. Mr. Leuchtenberger received his M.B.A. from the Yale School of Management and his B.A. from Wake Forest University. He is currently the non-executive Chairman of the Board of Directors of Xenetic Biosciences, a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. He is a director and past chairman of the Massachusetts Biotechnology Council Board of Directors and currently serves as a trustee for Beth Israel Deaconess Medical Center and Chairman of the Advisory Committee for the MassDevelopment Emerging Technology Fund. He is a co-founder of Albor Biologics, Inc. and Alvos Therapeutics, Inc.

Liz Lewis

Liz Lewis is Chief Counsel & Chief Compliance Officer Millennium: The Takeda Oncology Company/Takeda Pharmaceuticals International Co. She has been instrumental in creating Millennium's legal and compliance functions that support the global oncology business and has played an integral role in the successful launch, commercialization and market expansion of VELCADE. Liz has more than 20 years of legal expertise advising manufacturers, payers and other ancillary providers in the health care life sciences space. Prior to Millennium, she served as a partner in the national health law practice of Epstein, Becker & Green, a D.C.-based law firm. She was inducted into the Takeda Leadership Institute, serves as the chair for various steering committees, and is an active participant in industry trade organizations, PhRMA and BIO, often being asked to provide legal and compliance leadership. Most recently, the Boston Business Journal named Liz as one of the top 20 "2014 Women to Watch" in the life sciences industry.

Antony Loebel, M.D.

Dr. Tony Loebel is Executive Vice President and Chief Medical Officer at Sunovion Pharmaceuticals Inc. He also serves as Head of Global Clinical Development for Sunovion and its parent company Sumitomo Dainippon Pharma Co., Ltd.

Dr. Loebel is a board-certified psychiatrist and scientist who joined Sunovion in 2007. He is a member of the Sunovion Executive Leadership Team and Board of Directors, as well as an Executive Officer of Sumitomo Dainippon Pharma in Japan. Dr. Loebel provides strategic direction and leadership of Sunovion R&D, with responsibility for global drug development and medical oversight of all investigational drugs and marketed products. Dr. Loebel led the global development of Latuda® (lurasidone HCl), the Company’s flagship product that is approved for the treatment of patients with schizophrenia and bipolar depression. He was also responsible for the development and FDA approval of Aptiom® (eslicarbazepine acetate) for the adjunctive treatment of patients with partial-onset seizures.

For his achievements in advancing new treatments for central nervous system disorders, the International Society for CNS Drug Development (ISCDD) presented Dr. Loebel with its 2015 Award for Leadership. Selected by PharmaVoice in 2013 as one of the "100 Most Inspiring People" in the pharmaceutical industry, Dr. Loebel is widely recognized by his peers as an innovative leader guided by his dedication to patients. Dr. Loebel has published more than 80 peer-reviewed scientific papers and approximately 600 abstracts and posters. He holds editorial positions at distinguished publications including CNS Spectrums, BMC Psychiatry and Schizophrenia Research. He is a Clinical Assistant Professor of Psychiatry at the New York University School of Medicine. Dr. Loebel serves on the Pharmaceutical Research and Manufacturers of America (PhRMA) Scientific Leadership Advisory Council and on the Massachusetts Biotechnology Council (MassBio) Board of Directors. Dr. Loebel is a Fellow of the American Psychiatric Association and a member of the American College of Neuropsychopharmacology (ACNP).

Lisa M. Olson, Ph.D.

Dr. Lisa Olson is Vice President, Immunology Research and ABC Site Head of AbbVie Bioresearch Center Inc. Dr. Lisa Olson is responsible for the oversight and strategic development of AbbVie's Immunology research  program, and is Site Head for the AbbVie Bioresearch Center in Worcester, MA.

Following a post-doctoral fellowship at the University of Chicago, Chicago, IL, Dr. Olson joined the faculty of  the OB/GYN Department, Washington University Medical School, St. Louis, MO. In 1998, Olson left  Washington University to lead the Women’s Health Program within the Nutrition Sector of Monsanto Corp.,  St. Louis, MO. Two years later, she joined the Arthritis and Inflammation Department at Pharmacia Corp, St.  Louis, MO which subsequently evolved into the Inflammation Department of Pfizer Corp, St. Louis, MO. Dr.  Olson joined AbbVie (formerly Abbott) in 2005 as Director, Pharmacology and has had roles of increasing  responsibility ever since. In 2008, she was promoted to Senior Director, Pharmacology and Discovery Safety,  Metabolism and Pharmokinetics and in 2010 became Divisional Vice President, Immunology Research. Dr.  Olson became Site Head of the AbbVie Bioresearch Center in 2012.

Dr. Olson received her Ph.D. degree at the University of Illinois, Urbana, IL in 1986. Dr. Olson has published over 30 peer reviewed articles in journals and has authored six patents. She currently serves on the Board of  Directors for the Massachusetts Biotechnology Council and is a Trustee for the Massachusetts Biomedical  Initiatives.

John Orloff

Dr. John J. Orloff, M.D.,is Global Head of Research and Development for Baxter BioScience,  In this role, Dr. Orloff is responsible for advancing the BioScience pipeline, enhancing the current R&D operating model and pursuing additional innovative opportunities for the business.  Dr. Orloff joined Baxter from Merck Serono Pharmaceuticals, where he served as global head of clinical development. Dr. Orloff was previously the Chief Medical Officer and Senior Vice President, Global Development, for Novartis Pharmaceuticals. Prior to that at Novartis, he held a number of roles with increasing responsibility, including Section Head for Bone Metabolism in Clinical Development, Vice President and Therapeutic Area Head of the Arthritis, Bone Metabolism, and Women’s Health division within Clinical Development and Medical Affairs, and Head of US Medical and Drug Regulatory Affairs. Dr. Orloff graduated magna cum laude from Dartmouth College, received his medical degree from the University of Vermont, and completed internal medicine training at the University of Pittsburgh, serving as Chief Medical Resident. Subsequently he finished his subspecialty fellowship training in Endocrinology and Metabolism at Yale University, where he served on the faculty as an Associate Professor of Medicine before moving on to Merck Research Labs to lead clinical programs in bone metabolism.

Paris Panayiotopoulos

Paris Panayiotopoulos is the President and Managing Director of EMD Serono, Inc., the U.S. affiliate of Merck Serono and the biopharmaceutical division of Merck KGaA, Darmstadt Germany. EMD Serono is one of the top U.S. biopharmaceutical companies focused exclusively on specialty care. EMD Serono integrates cutting-edge science, innovative products, patient-directed devices as well as industry-leading patient support and access programs.

In his role at EMD Serono, Mr. Panayiotopoulos is responsible for all areas of the company’s business.

Mr. Panayiotopoulos joined EMD Serono in 2013 after serving as President and Managing Director Merck Serono’s subsidiary in Japan, where he demonstrated his leadership in driving dramatically improved business performance as well as cultural and organizational change. Mr. Panayiotopoulos has ten years of experience at Merck Serono, where he has held positions of increasing responsibility across multiple franchises and regions, including Head of Western Europe Operations, Director of Global Marketing, Global Commercial Team Leader and Head of the COO Office.

Prior to joining Merck Serono, Mr. Panayiotopoulos served in roles across multiple therapeutic areas and global brands at Eli Lilly & Company, based in the United Kingdom.

EMD Serono established operations in Massachusetts more than 40 years ago and the company continues to expand its presence, including the EMD Serono Research & Development Institute in Billerica, MA, which drives drug development from early-stage drug discovery research to clinical development and medical use. The combined organizations of EMD Serono and EMD Millipore make EMD the fifth largest life science company in Massachusetts.

Michael Pellini, MD

Dr. Pellini joined Foundation Medicine as President and Chief Executive Officer in May 2011, bringing a breadth of experience in life sciences and the clinical diagnostics and laboratory industries to the company. Dr. Pellini came to Foundation Medicine from Clarient, a GE Healthcare Company, where he held the position of President and Chief Operating Officer. Dr. Pellini joined GE Healthcare through the integration of Clarient, Inc., where he worked with the company’s leadership team to drive operational excellence and reimbursement strategies in parallel with the development and commercialization of multiple diagnostic tests. Dr. Pellini’s leadership was instrumental in building Clarient to the highly successful acquisition by GE Healthcare in October 2010.

Prior to his tenure with Clarient, Dr. Pellini served as Vice President, Life Sciences at Safeguard Scientifics, Inc. where he leveraged his business and medical expertise to explore new market opportunities and to support Safeguard’s partner companies. Prior to Safeguard, he was Executive Vice President and Chief Operating Officer at Lakewood Pathology Associates, a national molecular pathology services company, which was acquired by Water Street Healthcare Partners in 2006. Previously, Dr. Pellini was an Entrepreneur-in-Residence at BioAdvance, where he was responsible for identifying early-stage life science opportunities. He also served as President and Chief Executive Officer of Genomics Collaborative, Inc., a Boston-based biotech firm that was acquired by SeraCare Life Sciences, Inc. in 2004.

Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College of Thomas Jefferson University. He is a board member of the Personalized Medicine Coalition and serves on the President’s Leadership Council of Jefferson Medical College.

Adelene Perkins

Adelene Perkins has served as Infinity Pharmaceuticals’ President and CEO since 2009 and as board chair since 2012. She has played an integral role in building the company, leading its transition from a platform to a product-based organization. She was the principal figure in structuring and restructuring Infinity's strategic relationships which have played a critical role in developing the company’s current product portfolio. Adelene has more than 25 years of international business experience in the biopharmaceutical industry, focused on building and leading high-caliber, cross-functional teams, corporate strategy licensing and business development, strategic finance, and product life cycle management. Adelene joined Infinity from TransForm Pharmaceuticals where she was an early member of the management team that built the company prior to its acquisition by J&J. Prior to Transform she was vice president of emerging businesses at Genetics Institute, now part of Pfizer. She joined GI from Bain & Company where she provided strategic and operational advice to clients in the healthcare industry. Adelene holds an M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is on the Boards of the Massachusetts Life Sciences Center, the Massachusetts Biotechnology Council, BIO (the Biotechnology Industry Organization), and the Villanova University College of Engineering, and is Vice Chairman of the Board of Project Hope.

Deanna Petersen

Deanna Petersen joined Shire in 2009 as Vice President of Business Development and now heads up all business development activity for the rare disease business unit and new therapeutic areas that are growth opportunities for the company.  Deanna is a broadly skilled senior executive with 20 years of leadership experience in global business development.  Deanna and her team are responsible for identifying and evaluating new business opportunities, and for negotiating all types of transactions including acquisitions (public and private), licenses and other partnerships and collaborations.  Prior to joining Shire, Deanna was Vice President of Business Development at Agenus Inc. and at Coley Pharmaceutical Group.  Deanna is on the Board of Directors for American DG Energy and for the Massachusetts Biotechnology Association, and was formerly on the Board of Directors for the Healthcare Businesswomen’s Association, Boston Chapter.  Deanna is a founding member of the BioPharma Executive Council in Boston, and is a member of the Licensing Executives Society.  Deanna holds a Bachelor of Science in Biology from Iowa State University and a Master of Business Administration from The University of Iowa. 

Alice Lin Pomponio

Alice Lin Pomponio is Head of Corporate Affairs—North America Science Affairs for AstraZeneca.  Her team works closely with scientific stakeholders in academia, government, and nonprofits to promote favorable external R&D environments and to proactively shape AstraZeneca’s global science policies.  Prior to joining AstraZeneca in 2012, Alice was Senior Director of Global Policy Programs at Genzyme Corporation where she focused on international innovation, health, and trade policy issues affecting patient access to biologics and orphan drugs.  Between 2000 and 2005 she served as Vice Consul and US Life Sciences and Healthcare Industry Advisor to the British Government with responsibility for US industry relations and strategic input into UK government life sciences initiatives.  She previously worked at US Office of Management and Budget (OMB) with responsibility for the US Department of Energy (DoE) Human Genome Program management review.  She conducted laboratory research at Viagene Inc and the MIT Whitehead Institute and has held product pricing and reimbursement roles at Genzyme.  Alice holds a Bachelor of Science in Biology from MIT and a Master’s in Public Policy from Harvard University. 

Steven Richter, Ph.D.

Dr. Richter is President & CEO at Microtest Laboratories Inc. With his expertise in Sterilization Sciences, Dr. Richter founded Microtest in 1984 after a 5-year career as a microbiologist at the U.S. Food & Drug Administration. Under his leadership, Microtest has provided the medical device, pharmaceutical, and biotechnology industries with premier testing and manufacturing support. Dr. Richter received a B.S. degree in Microbiology from the University of Massachusetts-Amherst, an M.S. degree Biological Sciences from the University of Massachusetts-Lowell, and a Ph.D. in Sterilization Sciences from Columbia Pacific University.

Rick Russell

Rick Russell is CEO of Ares Allergy Holdings Inc, and President and CEO of Greer Laboratories. Prior to this, Mr. Russell served as Sunovion's Chief Commercial Officer, providing leadership for North American and U.K. commercial organizations. Mr. Russell has more than 20 years of experience leading commercial operations and in developing and implementing sales and marketing activities for major pharmaceutical brands.

Prior to joining Sunovion, Mr. Russell held the position of U.S. Executive Vice President, Neurodegenerative Diseases and Rheumatology at EMD Serono, where he managed all sales and marketing activities for the multiple sclerosis franchise.   Prior to his role at EMD Serono, Mr. Russell was Vice President Marketing at Sanofi-Aventis leading one of the largest pharmaceutical products in the United States.  Earlier in his career, Mr. Russell held several roles in sales and marketing leadership.  His pharmaceutical experience spans several therapeutic areas ranging from central nervous system (CNS) disorders, women’s health, cardiovascular disease and neurodegenerative disorders. 

Mr. Russell holds a B.A. in Chemistry from Bates College and a M.S. in Organic Chemistry from the University of New Hampshire.

Amit K. Sachdev

Mr. Sachdev joined Vertex in July 2007 and currently serves as the Senior Vice President, Public Policy and Government Affairs. In this role, he leads the company's corporate communications, government affairs and public policy functions.

Mr. Sachdev came from Biotechnology Industry Organization (BIO) where he served as Executive Vice President, Health. At BIO, he was the senior executive responsible for managing BIO's health policy department and its Governing Board. Mr. Sachdev is the former Deputy Commissioner for Policy at the U.S. Food and Drug Administration (FDA) where he also held several other senior appointments from 2002 to 2005. At FDA, he oversaw the development of all FDA policies, regulations and legislation.

From 1998 to 2002, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the U.S. House of Representatives. From 1993 to 1997, Mr. Sachdev practiced law, first at the Chemical Manufacturers Association, and then with the law firm of Ropes and Gray. Mr. Sachdev received a B.S from Carnegie Mellon University, and a J.D. from Emory University School of Law.

Frank E. Thomas

Frank Thomas joined AMAG Pharmaceuticals, Inc. as Executive Vice President and Chief Financial Officer in August 2011. In November 2011, Mr. Thomas was appointed to the role of Chief Operating Officer of AMAG.

During his 19-year career, Mr. Thomas has held a variety of senior executive roles in the life sciences industry. From 2008 to 2011, Mr. Thomas served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, a medical diagnostics company focused on reproductive medicine where he established the company’s manufacturing, distribution and business processes in support of product development and commercialization. Prior to his time with Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., where he was promoted to President and Chief Executive Officer from the position of Senior Vice President and Chief Financial Officer to lead a turnaround effort, refocus the company on new product opportunities and improve operational execution. Mr. Thomas also served on the Board of Directors of Critical Therapeutics until 2008. Prior to 2004, he served as Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a development-stage biotechnology company focused on a cardiovascular product. Mr. Thomas’s prior positions include senior director of finance, corporate controller and audit roles with Mechanical Dynamics Inc., and Arthur Anderson LLP from 1992 to 2000, respectively. Since 2007, Mr. Thomas has been a member of the Board of Directors of the Massachusetts Biotechnology Council.

Mr. Thomas holds a B.B.A. in Business Administration from the University of Michigan, Ann Arbor.

Kathleen Weldon Tregoning

Kathleen W. Tregoning joined Biogen Idec as Vice President, Government Strategy in May 2006.  Her team is responsible for overseeing global government relations and public policy analysis for Biogen Idec out of the company’s office in Washington, D.C., focusing primarily on reimbursement, regulatory, and intellectual property policy issues.   

Prior to joining Biogen Idec, Ms. Tregoning was a professional staff member in the U.S. Congress, working for the chairmen of the House of Representatives Ways & Means Committee, the House Energy & Commerce Committee, and the Senate Budget Committee.  In these positions she was a key resource for members of Congress on a wide range of health care issues, including Medicare, Medicaid, prescription drugs, disease management, health care information technology, and post-acute care.  Ms. Tregoning was a lead staff member in the drafting of the Medicare Modernization Act of 2003 and the Deficit Reduction Act of 2005.  

Ms. Tregoning previously served as an Assistant Deputy Mayor for Policy and Budget for Mayor Richard Riordan in Los Angeles.  She began her career as a management consultant with Andersen Consulting, developing business strategies for clients across a range of industries.  She received her undergraduate degree in International Relations from Stanford University and her master’s degree in Public Policy from the Kennedy School of Government at Harvard University.   She lives in Virginia with her husband John and their two children. 

Charles Wilson, Ph.D.

Charles 'Chuck' Wilson, PhD serves as Vice President and Global Head of Strategic Alliances, leading the group responsible for externally oriented research at the Novartis Institutes for BioMedical Research (NIBR), the business unit of Novartis responsible for drug discovery and early clinical development. Partnering efforts include broad academic relationships to improve the understanding of basic disease processes, biotech collaborations focused on new drug discovery technologies, and in-licensing of compounds that have yet to reach clinical proof-of-concept.  Prior to joining Novartis, Chuck founded and led Archemix, a biotech company focused on the development of aptamers as therapeutics.  Responsible initially as its Chief Technology Officer for developing the company's technology platform and managing its drug discovery efforts, he moved into a business role focused on establishing partnerships with large pharma and biotech companies.  Before moving into industry, Chuck was an Associate Professor of Molecular, Cellular, and Developmental Biology at the University of California, Santa Cruz.  There he determined the first x-ray crystal structures of RNA aptamers bound to their targets.  Formally trained in structural biology and molecular biology, Chuck received his PhD from the University of California, San Francisco and his post-doctoral training in the Department of Molecular Biology at Massachusetts General Hospital.

Lawrence S. Wittenberg

Mr. Wittenberg, a partner in Goodwin Procter's Technology Companies Group and co-chair of its Life Sciences Practice, focuses his practice in matters involving life sciences. He joined Goodwin Procter in 2005.

Mr. Wittenberg has been an active participant in the life sciences industry since the mid-1980s, and his practice focuses exclusively on biotechnology and other life sciences companies. His clients range in size from start-ups to public companies, and he assists them with a full range of corporate and intellectual property transactions, including venture capital financings, public offerings, mergers and acquisitions, strategic alliances, joint ventures, licenses and technology transfer agreements, as well as with general legal and strategic advice.

Mr. Wittenberg also represents venture capital groups with respect to their investments in life sciences companies and investment banks in connection with public and private financings. He has structured and negotiated corporate partnering transactions with numerous world-wide pharmaceutical companies.

Prior to joining Goodwin Procter, Mr. Wittenberg was a partner in the Business Practice Group at Testa, Hurwitz & Thibeault, where he headed the Life Science Practice. Mr. Wittenberg holds a J.D. from Harvard Law School and a Bachelor's degree from Cornell University.

Robert Gottlieb

Robert Gottlieb, who is the Principal at the communications and strategy consulting firm, RMG Associates,  has more than 30 years of experience in the biotechnology and pharmaceutical industries as a consultant on strategy and communications, in-house communications director, and journalist.  

He has substantial experience and a strong track record in work with well over 100 companies and organizations ranging from start-ups in and outside of the U.S. to multi-nationals. Robert and RMG Associates bring particular expertise in corporate positioning, external and internal communications strategy, and preparation for financing and partnering.  He has helped more than 20 clients develop business plans to support venture and public financings.  

Robert co-founded Feinstein Kean Healthcare (now a division of Ogilvy Public Relations Worldwide), a Massachusetts-based communications and business consulting firm focused exclusively on biotechnology, pharmaceutical, and related healthcare organizations. Robert has been an active member of the biotechnology community in Massachusetts for more than 25 years. Robert served as an advisor to the Massachusetts Biotechnology Council for over 15 years. He also participates as a mentor in MIT’s Venture Mentoring Service and as a member of the Board of Directors of the New England Israel Business Council.

Previously, Robert directed press relations and corporate communications at Biogen Inc., during a period that laid the foundation for the company’s turnaround. He also managed communications for Biogen’s Research and Development Limited Partnership.

Prior to Biogen, Robert was executive editor of F-D-C Reports, “The Pink Sheet,” During his ten-years at “The Pink Sheet,” he covered the FDA and drug regulation, pharmaceutical business and the emergence of biotechnology as an industry.  He also founded a reference publication for the pharmaceutical and biotechnology industries, The NDA Pipeline, which has been published annually for more than 25 years.

Robert holds a B.A. degree from Trinity College (Connecticut).

William P. McDermott

Bill McDermott is a partner in the law firm of McDermott, Quilty & Miller LLP.  He specializes in state and federal relations in the government affairs and business strategies practice.  With a wealth of public and private sector experience, Bill's primary focus is on governmental relations, regulatory law and procurement for clients involved in biotechnology, health care, real estate development and technology-based industries.

Prior to joining the firm, Bill was a founding member of ML Strategies and attorney with the law firm of Mintz, Levin.  Bill was Senior Vice President of Government Affairs at ML/MLS from 1990-2000.  Among his accomplishments, Bill has successfully directed a number of major initiatives through the Massachusetts State Legislature, including the passage of the Economic Stimulus I and II bills, the Stem Cell bill and the $1B Life Sciences Initiative.

Bill's extensive experience in public service includes his appointment as Chief Counsel to the Massachusetts State Senate's Ways and Means Committee in 1988, and his appointment in 1983 as Undersecretary and General Counsel to the Executive Office of Economic Affairs for the Commonwealth of Massachusetts, where he completed his service as Acting Secretary.  Prior to returning to Massachusetts, Bill worked for the United States Congress in various capacities, including a position with Congressman Joe Moakley, former Chairman of the Rules Committee.

Bill has served as Legislative Counsel to the Massachusetts Biotechnology Council since 1994.

Bill received his Law Degree from American University and his Master's Degree in Public Administration from the John F. Kennedy School of Government at Harvard University.  He also completed graduate studies at Georgetown University and received his Bachelor's Degree from Boston College.  He is a member of the Massachusetts Bar.

About MassBio

MassBio is a not-for-profit organization committed to advancing Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives.

Founded in 1985, MassBio represents over 650 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, and works to advance policy and promote education, while providing member programs and events, industry information, and services.

image of rss iconLatest Updates